Abbott Laboratories
Income Statement
| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.16B | $11.46B | $11.37B | $11.14B | $10.36B | $10.97B | $10.64B | $10.38B |
| Cost of Revenue | $4.89B | $4.92B | $5.08B | $4.85B | $4.47B | $4.94B | $4.70B | $4.60B |
| Gross Profit | $6.27B | $6.54B | $6.29B | $6.29B | $5.89B | $6.03B | $5.94B | $5.77B |
| Gross Margin | 56.2% | 57.0% | 55.4% | 56.4% | 56.9% | 55.0% | 55.8% | 55.6% |
| Operating Expenses | ||||||||
| Research & Development | $767.0M | $735.0M | $766.0M | $725.0M | $716.0M | $749.0M | $713.0M | $698.0M |
| SG&A Expense | $3.74B | $3.13B | $3.05B | $3.09B | $3.06B | $2.91B | $2.90B | $2.94B |
| Operating Income | $1.35B | $2.25B | $2.06B | $2.05B | $1.69B | $1.91B | $1.86B | $1.67B |
| Operating Margin | 12.0% | 19.6% | 18.1% | 18.4% | 16.3% | 17.4% | 17.5% | 16.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $1.45B | $2.36B | $2.18B | $2.15B | $1.78B | $2.03B | $1.94B | $1.61B |
| Income Tax Expense | $372.0M | $582.0M | $536.0M | $371.0M | $453.0M | $-7.20B | $294.0M | $305.0M |
| Net Income | $1.08B | $1.78B | $1.64B | $1.78B | $1.33B | $9.23B | $1.65B | $1.30B |
| Net Margin | 9.6% | 15.5% | 14.5% | 16.0% | 12.8% | 84.1% | 15.5% | 12.5% |
| EPS (Basic) | $0.62 | $1.01 | $0.94 | $1.02 | $0.76 | $5.29 | $0.94 | $0.74 |
| EPS (Diluted) | $0.61 | $1.01 | $0.94 | $1.01 | $0.76 | $5.26 | $0.94 | $0.74 |
| Shares Outstanding (Basic) | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B |
| Shares Outstanding (Diluted) | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B |
| Dividends Per Share | $0.63 | $0.63 | $0.59 | $0.59 | $0.59 | $0.59 | $0.55 | $0.55 |